Drug Profile
PEN 110
Alternative Names: INACTINE; INACTINE™ Pathogen Inactivation red blood cell product; INACTINE™ Pathogen Reduction System for Red Cells; PEN110Latest Information Update: 05 Jul 2005
Price :
$50
*
At a glance
- Originator Panacos Pharmaceuticals Inc
- Class Polyamines
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Graft-versus-host disease; Infections
Most Recent Events
- 05 Jul 2005 The INACTINE system is available for licensing (http://www.vitechnologies.com)
- 05 Jul 2005 Discontinued - Phase-III for Infections in USA (Extracorporeal)
- 05 Jul 2005 Discontinued - Preclinical for Graft-versus-host disease in USA (Extracorporeal)